Product image of Lindynette 30 (Ethinylestradiol, Gestodene) supplied by GNH India

Lindynette 30

Active Ingredient:
Ethinylestradiol, Gestodene
Origin:
EU

Lindynette 30 (Ethinylestradiol, Gestodene)

Ethinylestradiol, the active ingredient in Lindynette 30, is a combined oral contraceptive presented as a 30 µg ethinylestradiol / 0.075 mg gestodene tablet for oral use. It prevents pregnancy and helps regulate menstrual cycles in women of reproductive age, while gestodene provides the progestogenic component that enhances efficacy and cycle control.

GNH India supplies Lindynette 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All shipments meet EU quality standards and are supported by comprehensive documentation.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lindynette 30, a combined oral contraceptive, is indicated for the following clinical situations:
  • Contraception: Provides reliable prevention of pregnancy when taken as prescribed.
  • Regulation of menstrual cycles: Promotes more predictable bleeding patterns and reduces cycle‑related symptoms.
  • Acne management: Improves hormonal acne in women who also require contraception.

How It Works

  • Ethinylestradiol binds to estrogen receptors, suppressing the hypothalamic‑pituitary‑gonadal axis and inhibiting the mid‑cycle surge of luteinizing hormone, while gestodene activates progesterone receptors to prevent ovulation, thicken cervical mucus, and alter the endometrial lining, collectively preventing fertilisation and implantation.

Side Effects

Lindynette 30 may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset, often transient.
  • Headache: tension‑type or migraine‑like pain.
  • Breast tenderness: swelling or discomfort.
  • Spotting or irregular bleeding: especially during the first months.
  • Mood changes: irritability or emotional fluctuations.
  • Weight gain: mild fluid retention.

Serious or Rare Side Effects

  • Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
  • Stroke: ischemic or hemorrhagic events.
  • Myocardial infarction: heart attack risk, particularly in high‑risk women.
  • Severe hypertension: sudden increase in blood pressure.
  • Liver tumor: benign hepatic adenoma.
  • Anaphylaxis: rare severe allergic reaction.

Precautions & Warnings

  • Before prescribing Lindynette 30, clinicians should consider several safety measures.
  • Assess cardiovascular risk: evaluate history of thromboembolic disease before initiating therapy.
  • Avoid in smokers over 35 years: increased risk of serious cardiovascular events.
  • Monitor blood pressure: ensure hypertension is controlled prior to and during use.
  • Review concomitant medications: consider drugs that induce hepatic enzymes and may reduce efficacy.
  • Counsel on missed tablets: advise specific steps to maintain contraceptive protection.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Avoid Interactions

Lindynette 30 can interact with other medicines, affecting its effectiveness or safety.

Major Interactions (Avoid)

  • CYP3A4 enzyme inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive effectiveness.
  • Potent anticoagulants (e.g., warfarin): combined use can increase risk of thrombotic events.

Moderate Interactions (Monitor Closely)

  • Antibiotics such as tetracycline: may slightly decrease absorption of estrogen.
  • Herbal supplements like St. John’s wort: can lower plasma levels of both hormones.
  • Antiepileptic drugs (e.g., phenytoin, phenobarbital): may require monitoring of contraceptive efficacy.

Frequently Asked Questions

Lindynette 30 is a combined oral contraceptive containing ethinyloestradiol and gestodene. It is prescribed to prevent pregnancy and to help regulate menstrual cycles in women of reproductive age, providing reliable birth control and more predictable bleeding patterns.

Ethinyloestradiol suppresses the release of gonadotropins from the pituitary, preventing the mid‑cycle surge of luteinising hormone that triggers ovulation. Gestodene activates progesterone receptors, further inhibiting ovulation, thickening cervical mucus, and altering the endometrial lining, together preventing fertilisation and implantation.

The dosing schedule for Lindynette 30 is determined by the prescribing clinician. Typically, the product is taken as a 21‑day active tablet sequence followed by a 7‑day hormone‑free interval, but the exact regimen must be confirmed with a qualified healthcare professional.

Lindynette 30 is not intended for use during pregnancy and should be discontinued if pregnancy occurs. Limited data exist for breastfeeding; the product is generally not recommended unless the benefits outweigh potential risks, and a physician should be consulted for individualized advice.

To order Lindynette 30, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lindynette 30 uses gestodene as the progestogenic component, which is a third‑generation progestin associated with a lower incidence of androgenic side effects compared with older agents like levonorgestrel. Efficacy in preventing pregnancy is comparable across combined oral contraceptives, while individual tolerability and metabolic profiles may differ.

Lindynette 30 tablets should be stored at ambient temperature, below 25 °C. Keep the product in its original blister pack, protect it from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain tablet integrity.

Lindynette 30 is taken orally, once daily, preferably at the same time each day. The typical regimen involves 21 consecutive active tablets followed by a 7‑day hormone‑free interval, during which withdrawal bleeding occurs. Patients should follow the specific instructions provided by their prescriber.

Serious risks include venous thromboembolism, stroke, myocardial infarction, severe hypertension, and rare liver tumors. Women should seek immediate medical attention if they experience unexplained chest pain, shortness of breath, severe headache, visual changes, or sudden swelling of the legs.

Lindynette 30 is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, known hypersensitivity to any component, active liver disease, certain hormone‑dependent cancers, or who are pregnant or breastfeeding. Smoking women over 35 years should also avoid this product due to increased cardiovascular risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Gestodene

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT